Mechanistically, our data suggest that hepatocyte SIRT6 likely inhibits the development of NAFLD by suppressing de novo lipogenesis, lipid droplet formation, the p53 pathway, and inflammation. This evidence concerns the gene TP53 and metabolic dysfunction-associated steatotic liver disease.